Last edition
News about "rCDI clinical trial"
Acurx Enrolls First Patient in PATHFINDER C. difficile Trial
Acurx Pharmaceuticals has announced the first patient enrolled in PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.
RCDI Clinical Trial | 01/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members